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The prevalence of gestational diabetes mellitus (GDM) in the developed world has increased at an alarming rate over the last few
decades. GDM has been shown to be associated with postpartum diabetes, insulin resistance, hypertension, and dyslipidemia. A
historyofpreviousGDM(pGDM),associatedornotwithanyofthesemetabolicabnormalities,canincreasetheriskofdeveloping
not only type 2 diabetes mellitus but also cardiovascular disease (CVD) independent of a diagnosis of type 2 diabetes later in life.
In this paper we discuss the relationship among inﬂammatory markers, metabolic abnormalities, and vascular dysfunction in
women with pGDM. We also review the current knowledge on metabolic modiﬁcations occurring in normal pregnancy and the
link between alterations of a normal metabolic state with the long-term maternal complications that may result in increased CVD
risk. Our review of studies on pGDM prompts us to recommend that these women be considered a population at risk for later
CVD events, which however could be avoided via the use of specially designed follow-up programs in the future.
1.Introduction
Gestational diabetes mellitus (GDM) is any degree of glucose
intolerance with onset or ﬁrst recognition during pregnan-
cy [1, 2]. In early gestation fasting blood glucose is lower
and insulin sensitivity decreases slightly. This is followed by
progressively increasing insulin resistance in the second and
third trimesters with a borderline increase of insulin produc-
tion or hyperinsulinemia. Furthermore, insulin resistance
occurs as a result of placental hormones that antagonize
insulin, estrogen, progesterone, human placental lactogen
(HPL), human placental growth hormone, cortisol, pro-
lactin, and tumor necrosis factor-alpha (TNF-α)[ 3]. The
abovediﬀerentpathophysiologicmechanismsaccompanying
pregnancy result in metabolic changes that allow for higher
postprandialmaternalglucose.Pregnancyisahyperinsuline-
mic state which may develop into impaired glucose tolerance
if insulin secretion is unable to compensate for pregnancy-
associated insulin resistance [3–5].
The condition of GDM is a state of chronic low-
grade subclinical inﬂammation characterized by abnormal
production of cytokine and mediators and activation of
a network of inﬂammatory signaling pathways. Although
the characteristic of GDM is insulin resistance, the exact
mechanism involved in this process is still unknown. The
increased insulin resistance during pregnancy has been,
as just described, attributed to cortisol and gestational
hormones, but more recent data have shown that cytokines
may also be involved in this process [6]. The most signiﬁcant
maternal risk is that of development of metabolic syndrome
characterized by central obesity, dyslipidemia, and insulin
resistance, which predispose to increased risk for coronary
artery disease, stroke, and type 2 diabetes later in life [7–11].
The incidence of type 2 diabetes in women with previous
GDM (pGDM) who were examined six weeks to 28 years
postpartum was estimated to range from 2.6% to 70%
[12, 13]. Other researchers found that women with pGDM
have a 18–50% risk of developing type 2 diabetes mellitus2 International Journal of Endocrinology
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Figure 1:MetabolicstatusduringpregnancyandpGDMmayresult
in outcomes later in life like metabolic abnormalities, DMII, CVD,
and DMII + CVD as it is shown following the arrows.
within 5 years following pregnancy [14–17], and diabetes
is an established risk factor for CVD [18, 19]. In addition,
women with a history of GDM are at increased risk of other
cardiovascular risk factors, such as obesity, hypertension,
dyslipidemia, and subclinical atherosclerosis [20–22]. It is
unclear whether women with a history of GDM who do
not subsequently develop type 2 diabetes mellitus are also
at an increased CVD risk in the future. The metabolic
abnormalities which accompany GDM preceding type 2
diabetesandwhichremainineﬀectduringthenaturalcourse
of the disease place women at high risk for CVD [23].
In this paper we review the interrelationship among
inﬂammatory markers, metabolic abnormalities, and endo-
thelium dysfunction in pGDM and discuss whether these
women could be considered at risk for cardiovascular disease
later in life. Based on the small amount of existing literature,
we discuss the inﬂammatory and metabolic abnormalities
underlying the status of pGDM and the potential that endo-
thelial dysfunction is a marker of future CVD risk. To our
knowledge, this is the ﬁrst paper presented in the literature
dealing with markers of CVD risk in women with a history
of gestational diabetes.
2.SurrogateMarkersof
IncreasedCardiovascularRisk
Although the majority of women with GDM return to nor-
mal glucose tolerance after delivery, they remain, as a group,
at substantially increased risk of developing type 2 diabetes
in later life, a known condition that leads to an increased risk
for CVD [24].
Inﬂammation may contribute to atherosclerosis by a va-
riety of mechanisms depending on the stage of the disease.
Circulating markers of systemic inﬂammation have been
shown to predict future CVD [25]. These markers include C-
reactive protein (CRP), proinﬂammatory cytokines such as
interleukin-6 (IL-6), and soluble adhesion molecules. Most
attention has been focused on CRP which, along with IL-6,
has been revealed in large prospective studies to be a
consistent predictor of future cardiovascular events [26, 27].
Epidemiological and experimental studies have estab-
lished the association of markers of subclinical inﬂamma-
tion with CVD, type 2 diabetes, and metabolic syndrome
(Figure 1). Pregnancy is a hyperinsulinemic state in which
the increased insulin resistance during pregnancy may be
attributed not only to gestational hormones but also possibly
to cytokines, which, as mentioned in Section 1, may play
ar o l e[ 28–30]. Increased levels of inﬂammatory markers
such as CRP, plasminogen activator inhibitor-1 (PAI-1),
and IL-6 are predictors of future establishment of type 2
diabetesandCVD[31–34].Adiponectin,apeptidewithanti-
inﬂammatoryproperties,hasinsomestudiesbeenassociated
with a decreased risk of type 2 diabetes and CVD [35, 36].
Markers of endothelial dysfunction, like circulating levels
of E-selectin, vascular adhesion molecule-1 (VCAM-1),
intercellular adhesion molecule 1 (ICAM-1), as well as
inﬂammatory parameters like CRP and IL-6, have been
reported to be associated with CVD in several studies
[37–42]. Furthermore, the adhesion molecules E-selectin,
VCAM-1, and ICAM-1 are thought to play a major role in
the pathogenesis of vascular disease [6]. These molecules
are markers of endothelial dysfunction and are expressed on
the endothelial wall in response to inﬂammatory mediators.
They contribute to the formation of atherosclerotic plaques
and can be detected in soluble form in the circulation
[43]. More reliable, and thus of great interest, are the
measurements of carotid intima media thickness (IMT)
and ﬂow-mediated vasodilatation (FMD). Both indexes have
been used in epidemiological studies as surrogate markers
of early atherosclerosis. Carotid IMT increases with age, is
correlated with cardiovascular risk factors, and identiﬁes
subjects at increased risk of severe coronary artery disease
and cardiovascular morbidity [37]. Intima media thickness
(IMT) is an ultrasound marker of CVD risk. Heiss et al.
in their study found positive relation of this marker to
cardiovascular risk factors and CVD risk [44].
Mediators of inﬂammation may exert pathologic action
by inducing vascular dysfunction, thus leading to many
of the diverse eﬀects of the insulin resistance condition,
like hypertension, dyslipidemia, and impaired ﬁbrinolysis
[62]. Insulin resistance has been associated with impaired
endothelial function, which interacts with coagulation
and hypoﬁbrinolysis [63, 64], while hypoﬁbrinolysis and
procoagulant activity are linked with increased risk for
cardiovascular events (Table 1). It is of note that raised
levels of circulating inhibitors of the ﬁbrinolytic system
have been observed in patients with insulin resistance [64].
Plasminogen activator inhibitor-1 (PAI-1) is elevated in a
variety of clinical situations that are associated with insulin
resistance and cardiovascular disorders [65].
Osteoprotegerin (OPG) is a glycoprotein, a soluble mem-
ber of the tumor necrosis factor (TNF) receptor superfamily,
which inhibits receptor activator of nuclear-factor-κB-ligand
(RANKL-) mediated osteoclastic bone resorption [66]. It
has been reported to be expressed in the arterial wall [67].
Elevated serum OPG levels have been found to be associated
with atherosclerosis [68].International Journal of Endocrinology 3
Table 1: Markers of increased CVD risk in normoglycemic women with GDM or pGDM.
Authors Number of subjects Months/years postpartum Markers of CVD risk
Kousta et al., 2003 [45] 78 3 years
↑ Insulin resistance
↑ lipidemia
Anastasiou et al., 1998 [46] 68 3–6 months ↓ FMD
Hu et al., 1998 [47] 37 2–4 years
↓ Acetylcholine induced
vasodilatation
Knock et al., 1997 [48] 32 During cesarean section
↑ Vascular pathology, vessel
myography
Paradisi et al., 2002 [49] 38 During GDM pregnancy ↓ FMD
Heitritter et al., 2005 [50] 48 1 year ↓ Adiponectin
Winzer et al., 2004 [51] 108 3 months ↓ Adiponectin
Bo et al., 2007 [52] 195 6-7 years
↑ E-selectin
↑ ICAM-1
↑ IMT
Thomaseth et al., 1997 [53] 10 1 year
↑ E-selectin
↑ VCAM-1
Lawrence et al., 2002 [54] 265 recent GDM ≈ E-selectin
Kautzky-Willer et al., 1997 [55] 41 3 months
↑ E-selectin
↑ VCAM-1
Shah et al., 2008 [56] 89.500 p GDM ↑ CVD events
Akinci et al., 2008 [57]7 6p G D M
↑ OPG
↑ IMT
Akinci et al., 2011 [58] 195 3 years ↑ OPG
Banerjee et al., 2011 [59] 29 2 years
↑ Vascular pathology, vessel
myography
Farhan et al., 2006 [60]7 0 r e c e n t G D M ↑ PAI-1
Madar´ asz et al., 2009 [61] 107 4 years
↑ CVD risk factors, disturbed
carbohydrate metabolism
Vessel stiﬀness measured by arterial tonometry is asso-
ciated with endothelial dysfunction and increased CVD risk
[69, 70].
3. StudiesinpGDMWomenforIdentiﬁcationof
the Risk of CardiovascularComplications
The study of women in the pGDM state serves as a
model for the detection of early metabolic abnormalities.
Normoglycemic women with pGDM have increased insulin
resistance and decreased endothelium-dependent vasodi-
latation when compared with women who had uncompli-
cated pregnancies [45, 46]. During the ﬁrst 3–6 months
postpartum, women with pGDM had impaired endothelial
function assessed by FMD, this tending to conﬁrm the
assumption that glucose metabolism derangement is closely
related to vascular dysfunction [46]. A cross-sectional study
showed that 2–4 years after the postpartum period, pGDM
had impaired acetylcholine-induced skin vasodilatation in
hand and foot, as assessed by laser Doppler ﬂow, when
compared with normal controls [47]. Two cohort studies
have reported signs of vascular endothelial dysfunction in
vitro and in vivo during pregnancies complicated by GDM.
The ﬁrst study evaluated vascular endothelial function in
smallsubcutaneousarteries dissected frombiopsies obtained
at cesarean section using vessel myograph and the second
during pregnancy with impaired glucose tolerance and
gestational diabetes mellitus assessing brachial artery FMD
[48, 49].
Heitritter et al. compared biochemical and hemody-
namicsurrogatemarkersofCVDinnondiabeticwomenwith
and without a history of GDM who were at least one year
postpartum and concluded that nondiabetic women with
pGDM have evidence of subclinical inﬂammation, hypoad-
iponectinemia, and early vascular dysfunction and may be
at increased risk of developing CVD [50]. Lower plasma
adiponectinconcentrationscharacterizewomenwithpGDM
by contrast to controls, independently of the prevailing
insulin sensitivity or the degree of obesity and are associated
with subclinical inﬂammation and atherogenic parameters
[51]. Bo et al. showed in their study that pGDM women
had higher values of markers of endothelial dysfunction
and IMT than controls and an increased future CVD risk;
however, few data are available concerning the association
between pGDM and inﬂammation markers of endothelial
dysfunction [52]. E-selectin and VCAM-1 concentrations
were found to be elevated in a cohort study of women
with pGDM one year after delivery [53]. A larger study
many months postpartum failed to display the same results4 International Journal of Endocrinology
[54]. Kautzky-Willer et al. demonstrated that pGDM was
characterized by persistently raised levels of E-selectin and
VCAM-1 12 weeks after delivery [55]. In a large population-
based study, women who had GDM in pregnancy compared
with controls were at higher risk of CVD events [56].
Akinci et al. observed that OPG serum levels tended to
be elevated in pGDM and moreover reported an association
with carotid IMT, thus showing that osteoprotegerin may
play a role in the pathogenesis of endothelial dysfunction
in these women [57]. Furthermore, a very recent study
conducted by the same group concluded that OPG was
relatedtoCVDriskfactorsandmetabolicsyndromeandmay
be involved in the development of CVD disorders in pGDM
[58]. Farhan et al. recorded elevated PAI-1 levels in pGDM
[60].
Another study examined the relationship between gly-
cemia during pregnancy and small artery function 2 years
postpartum. In this study subcutaneous arteries from gluteal
fat biopsy were examined as to structure, stiﬀness, and vaso-
constrictor response using myography. The results showed
that vascular pathology is detectable very early in women at
riskoftype2diabetes[59].Studyingtheprevalenceofabnor-
mal glucose tolerance and metabolic syndrome in a cohort
of pGDM, the results demonstrated disturbed carbohydrate
metabolism and a clustering of CVD factors in these women
[61, 71].
Surrogate markers of increased cardiovascular risk in
population-based studies are commonly used in routine
p r a c t i c e .H o w e v e r ,t h o u g hi ns t u d i e so fp G D Mm a r k e r sa r e
used that link this condition with future CVD risk [72], the
evidence is as yet inadequate for the markers to be applied
in the routine followup of these women. Nevertheless, the
aforementioned studies are promising, as several of these
biochemical and hemodynamic markers may in future prove
to be of great value in follow-up programs, contributing to
reducing the risk in pGDM for cardiovascular morbidities
later in life.
4. Conclusions
It has been shown that women with pGDM are more insulin
resistant than women with normal carbohydrate tolerance
during their pregnancies. Diabetic complications may be in
progress during the phase of insulin resistance in pregnancy
even in the absence of hyperglycemia, while furthermore
there is evidence that pGDM is associated with postpartum
diabetes, insulin resistance, hypertension, and dyslipidemia.
A history of pGDM can increase the risk of developing not
only type 2 diabetes mellitus, which is a major risk factor
for the development of cardiovascular disorders, but also
CVD independent of the presence of type 2 diabetes. Also
mentioned in this paper is the fact that a number of studies
have reported pGDM to be additionally associated with the
increased prevalence of metabolic syndrome, an important
factor of cardiovascular disorders.
Havingreviewedthecurrentliteratureconcerningthere-
lationship between inﬂammatory markers, metabolic abnor-
malities, and vascular dysfunction in pGDM, we proceeded
to evaluate, for the ﬁrst time to our knowledge, the sum total
of this information for the purpose of seeking to identify
women at future risk. We additionally reviewed the current
knowledge on normal metabolic modiﬁcations that occur in
pregnancy and the link between these normal modiﬁcations
and the ensuing long-term complications in this group of
women. Based on the evidence related to pGDM, we suggest
that these women be considered at an increased risk for
subsequent cardiovascular morbidity. Identifying women at
increasedriskfordevelopingcardiovascularmorbiditiesand,
at a later date, placing them in follow-up programs that
will include the use of established selected markers, has
the potential to substantially hold back their CVD risk
in terms of both, lower incidence and reduced severity of
cardiovascular events later in life.
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